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Renal impairmentTelavancin biological activity, determined by serum titers against a reference strain of Staphylococcus aureus, was
maintained in the serum of subjects with severe renal impairment or end-stage renal disease suggesting that
there is no apparent effect of renal function on in vitro activity of telavancin.
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(http://creativecommons.org/licenses/by-nc-sa/3.0/).The Phase 3 Assessment of Telavancin in Complicated Skin and Skin
Structure Infections (cSSSIs; “ATLAS”) clinical program demonstrated
non-inferiority of telavancin to vancomycin for treatment of cSSSIs
(Stryjewski et al., 2008). In an analysis of telavancin-treated patients
from the ATLAS trials, lower cure rates were observed in patients with
moderate and severe baseline renal impairment compared with pa-
tients with normal renal function or mild renal impairment
(Theravance, Inc., 2012). This study was conducted to determine
whether the observed differences in cure rates may be due to reduced
biological activity of telavancin in the serum of patients with renal im-
pairment. To investigate this question, telavancin biological activity, as
determined by serum titers against a reference strain of Staphylococcus
aureus, was compared between non-infected subjects with severe renal
impairment and end-stage renal disease (ESRD) and subjects with nor-
mal renal function.
A total of 45 men and women (aged 27–73 years) were enrolled,
with 15 in each of 3 renal function cohorts, based on estimated
creatinine clearance (CLCR) according to the Cockcroft–Gault formula
(Cockcroft and Gault, 1976), normal renal function (CLCR N80 mL/min),
severe renal impairment (CLCR b30 mL/min), and ESRD (subjects treated
routinely with hemodialysis). The CLCR was estimated using the subject's
ideal body weight; actual body weight was used if it was less than ideal
body weight.
A single 7.5 mg/kg (of total body weight) dose of telavancin was
administered intravenously over 1 h. This dosewas selected tominimize
potential toxicity while being high enough to evaluate telavancin con-
centration in blood samples. Blood samples were collected just before
dosing; at end of infusion; and at 2, 4, 6, 8, 12, 24, 30, 36, and 48 h1-650-808-6464.
re).
c. This is an open access article undafter the start of the infusion. Subjects in the ESRD group also had sam-
ples collected at 54, 60, and 72 h after the start of the infusion. Subjects
with ESRD underwent hemodialysis prior to telavancin administration
and prior to the collection of the pre-dose sample. Subjects resumed
their normal hemodialysis schedule after study completion.
Telavancin plasma concentrationsweremeasured by liquid chroma-
tography tandem mass spectrometry (LC/MS/MS). Biological activity
was assessed by serum titers (measured using serial 2-fold dilutions in
sterile, pooled human serum) against a susceptible reference strain of
Staphylococcus aureus (ATCC 29213), according to methods of the Clin-
ical and Laboratory Standards Institute (CLSI, 1999). Biological activity
was measured by serum inhibitory titer (SIT; the highest titer of
serum from telavancin-treated subjects that inhibited visible bacterial
growth in the test wells) and serum bactericidal titer (SBT; the highest
titer of serum from telavancin-treated subjects that produced 99.9% kill-
ing compared with the original bacterial suspension of 105 CFU/mL).
The telavancin MIC for the test organism using the CLSI standard
methods approved at the time this study was undertaken was
0.25–0.5 μg/mL on different testing days (within the CLSI published
quality control range for telavancin) (CLSI, 2011).
Two populations were deﬁned for the analysis; the safety analysis
set (n = 45), which included all enrolled subjects who received any
study drug; and the pharmacokinetic analysis set (n = 44), which in-
cluded all safety analysis set subjects whose pharmacokinetic data
were adequate for the calculation of primary pharmacokinetic parame-
ters. Pharmacokinetic parameters were calculated using non-
compartmental methods with WinNonlin® Professional (version 5.0.1;
Pharsight, Sunnyvale, CA, USA). Descriptive statisticswere used to sum-
marize subject baseline characteristics and pharmacokinetic parame-
ters. Comparisons of subjects in the severe renal impairment and
ESRD groups with the normal renal function group were performeder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Fig. 1.Mean plasma concentrations of telavancin over time (A), mean SITs over time (B),
and mean antibiotic inhibitory titer versus mean plasma telavancin concentration (C).
328 S.L. Barriere et al. / Diagnostic Microbiology and Infectious Disease 80 (2014) 327–329using analysis of variance (ANOVA) on natural log-transformed area
under the concentration–time curve from 0–48 h (AUC48) values with
renal function group as a ﬁxed effect. Within the ANOVA, 90% conﬁ-
dence intervals were constructed for the ratio of the geometric means.
At baseline, subjects in the normal renal function group, severe renal
impairment group, and ESRD group were mostly male (93.3%, 60.0%,
and 73.3%, respectively) and mostly white (86.7%, 80.0%, and 53.3%, re-
spectively). Mean (SD) subject age was 53.3 (9.7), 58.3 (11.9), and 54.8
(7.9) years, respectively, and CLCR was 96.3 (10.9), 21.4 (4.2), and 9.7
(1.9) mL/min, respectively, for the normal renal function, severe renal
impairment, and ESRD groups.
As previously reported (Duchin et al., 2004), telavancin plasma con-
centrations, as determined by LC/MS/MS, were increased in subjects
with severe renal impairment and ESRD compared with subjects with
normal renal function (Fig. 1A). The SIT assay also indicated higher
telavancin concentrations in subjects with severe renal impairment
and ESRD compared with subjects with normal renal function(Fig. 1B). The relationship between the mean SIT values obtained
from the potency assay and the mean plasma concentration obtained
by the bioanalytic assay were linear across the 3 groups across all time
points (Fig. 1C).
Telavancin pharmacokinetic parameters for the 3 renal function
groups are presented in Table 1. Telavancin exposures (AUC48) deter-
mined by LC/MS/MS were 2.1-fold and 2.5-fold higher in subjects
with severe renal impairment and ESRD, respectively, compared with
subjects with normal renal function (Table 1). Similarly, area under
the inhibitory concentration–time curve from0–48 hArea under the in-
hibitory curve (AUIC48) (ie, SITmin) values determined from the SIT
assaywere 1.9-fold and 2.1-fold higher in subjectswith severe renal im-
pairment and ESRD, respectively, compared with subjects with normal
renal function (Table 1).
At least 1 treatment-emergent adverse event was experienced by
51.1% (23/45) of subjects, with similar frequency in each of the 3 groups
(46.7%, 53.3%, and 53.3% for the normal renal function, severe renal im-
pairment, and ESRD groups, respectively). Only dysgeusia (46.7%, 26.7%,
and 13.3%, respectively), headache (13.3%, 26.7%, and 13.3%, respective-
ly), and nausea (0%, 6.7%, and 13.3%, respectively) occurred in more
than 1 subject.
Telavancin produced potent and prolonged in vitro bactericidal
activity against the strain of S. aureus tested in the serum of all
subjects, including those with severe renal impairment and ESRD. No
apparent effect of renal function on the antimicrobial activity of
telavancin was observed. Although use of telavancin in individuals
with CLCR≤50mL/min should be considered only when the anticipated
beneﬁt to the patient outweighs the potential risk, the present results
provide assurance that biologic activity is not impaired if telavancin is
prescribed to patients with poor renal function using appropriate
caution. Despite a lower dose than was used in the ATLAS studies
(7.5 mg/kg versus 10 mg/kg), high telavancin concentrations/titers
and extended activity were observed, suggesting that there is no loss
of biological activity in patients with severe renal impairment and
ESRD. The approximate doubling of telavancin exposure in patients
with severe renal impairment and ESRD is consistent with previously
reported observations (Duchin et al., 2004). This suggests that other fac-
tors may have been responsible for lower cure rates observed in the
ATLAS studies. These data contribute to the information available re-
garding appropriate dosing of telavancin in patients with ESRD.
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Table 1
Telavancin pharmacokinetic parameters and statistical analyses of the effect of renal impairment on telavancin exposure.
Assay Parameter Normal (n= 15) Severe renal impairment (n= 15) ESRD (n= 14)
LC/MS/MS Cmax, mean (SD) μg/mL 76 (12) 109 (109) 111 (127)
tmax, mean (SD) h 0.996 (0.013) 0.992 (0.017) 1.082 (0.267)
AUC48, mean (SD) μg * h/mL 539 (57) 1158 (266) 1336 (269)
AUCinf, mean (SD) μg * h/mL 541 (58) 1366 (345)a 1651 (461)
CLtot, mean (SD) L/h 1.266 (0.241) 0.493 (0.139)a 0.438 (0.170)
Vz, mean (SD) L 9.479 (1.899) 11.521 (3.487)a 8.345 (3.803)
t1/2, mean (SD) h 5.225 (0.768) 18.565 (6.494) 15.058 (8.949)
LS geometric mean exposureb, μg * h/mL 536 1130 1309
LS geometric mean ratioc, % of control (90% CI) - 210.99 (187.63, 237.26) 244.33 (216.83, 275.33)
SIT SITmax, mean (SD) 290 (90) 367 (277) 302 (228)
tmax, mean (SD) h 0.996 (0.013) 0.992 (0.017) 1.011 (0.036)
AUIC48/SITmin mean (SD) 1668 (517) 3192 (951) 3450 (778)
LS geometric mean exposureb, μg * h/mL 1602 3076 3377
LS geometric mean ratioc, % of control (90% CI) - 192.08 (163.62, 225.49) 210.84 (179.09, 248.22)
AUCinf = area under the concentration-time curve from 0 extrapolated to inﬁnity; Cmax = maximum plasma concentration; CI = conﬁdence interval; CLtot = total plasma clearance;
LS = least squares; t1/2 = half-life; tmax = time of occurrence of maximum plasma concentration; Vz = apparent volume of distribution during terminal phase.
a n= 13.
b Derived from analysis of variance on natural log-transformed AUC48 with renal function group as a ﬁxed effect.
c Severe renal impairment and ESRD versus normal renal function.
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